Inhibitory Effect of TNF-α on Malaria Pre-Erythrocytic Stage Development: Influence of Host Hepatocyte/Parasite Combinations

Nadya Depinay1,2, Jean Francois Franetich3,4, Anne Charlotte Grünér1,2,5, Marjorie Mauduit1,2,5, Jean-Marc Chavatte6, Adrian J. F. Luty7, Geert-Jan van Gemert7, Robert W. Sauerwein7, Jean-Michel Siksik8, Laurent Hannoun8, Dominique Mazier3,4,9, Georges Snounou3,4,6,9, Laurent Rénia1,2,5


Abstract

Background: The liver stages of malaria parasites are inhibited by cytokines such as interferon-γ or Interleukin (IL)-6. Binding of these cytokines to their receptors at the surface of the infected hepatocytes leads to the production of nitric oxide (NO) and radical oxygen intermediates (ROI), which kill hepatic parasites. However, conflicting results were obtained with TNF-α possibly because of differences in the models used. We have reassessed the role of TNF-α in the different cellular systems used to study the Plasmodium pre-erythrocytic stages.

Methods and Findings: Human or mouse TNF-α were tested against human and rodent malaria parasites grown in vitro in human or rodent primary hepatocytes, or in hepatoma cell lines. Our data demonstrated that TNF-α treatment prevents the development of malaria pre-erythrocytic stages. This inhibitory effect however varies with the infecting parasite species and with the nature and origin of the cytokine and hepatocytes. Inhibition was only observed for all parasite species tested when hepatocytes were pre-incubated 24 or 48 hrs before infection and activity was directed only against early hepatic parasite. We further showed that TNF-α inhibition was mediated by a soluble factor present in the supernatant of TNF-α stimulated hepatocytes but it was not related to NO or ROI. Treatment TNF-α prevents the development of human and rodent malaria pre-erythrocytic stages through the activity of a mediator that remains to be identified.

Conclusions: Treatment TNF-α prevents the development of human and rodent malaria pre-erythrocytic stages through the activity of a mediator that remains to be identified. However, the nature of the cytokine-host cell-parasite combination must be carefully considered for extrapolation to the human infection.

Introduction

Tumour necrosis factor (TNF)-α is a cytokine with pleiotropic effects including anti-microbial activities [1]. In malaria infections, it has been shown that TNF-α could have both beneficial and detrimental effects. TNF-α is detected in the circulation during the erythrocytic phase of the infection in humans [1–3] and in mice [4,5]. In both hosts, high levels of this cytokine have been associated with malarial pathology such as fever [6], and cerebral malaria [3,5]. On the other hand, TNF-α has also been shown to have a potent anti-parasitic activity. Administration of recombinant TNF-α protected against blood stage infection with Plasmodium chabaudi in mice [7], while mice deficient for TNF-α controlled P. chabaudi adami blood infections less efficiently [8]. In humans, sustained high levels of TNF-α were associated with rapid clearance of fever and parasites [9]. There are controversial observations concerning the role of TNF-α against the pre-erythrocytic (PE) stages of the malarial infection. Schofield et al. reported that recombinant human TNF-α directly inhibited P. berghei grown in vitro in the HepG2 human hepatoma cell line, and in vivo in rats and mice [10]. However, we have previously found that P. yoelii parasites grown in cultured purified mouse primary hepatocytes were unaffected by TNF-α, whereas this cytokine inhibited the hepatic development of this parasite in vivo [11]. We
then showed for this rodent malaria model that the inhibitory effect observed in vivo was actually mediated by the IL-6 secreted by non-parenchymal liver cells in response to TNF-α stimulation [11]. Thus depending on the host/parasite combination, different effects of TNF-α on PE parasites were reported. In this study, we wished to re-assess the role of some of the biological and experimental parameters on the inhibition of *Plasmodium* hepatic stages observed in in vitro assays of TNF-α activity.

**Materials and Methods**

**Ethics**

All experiments and procedures involving mice were approved by the “Direction Départementale des Service Vétérinaires de Paris, France” (Authorisation No 75–129) and performed in compliance with regulations of the French Ministry of Agriculture for animal experimentation (1987). Human liver fragments used to prepare primary hepatocyte cultures were collected after written informed consent from patients undergoing a partial hepatectomy. The experimentation was performed in compliance with the French ethical regulations, and were further purified over a 40% Percoll gradient. Human hepatocyte purity and viability were >99% as assessed by Trypan blue dye exclusion. Mouse and human hepatocytes were seeded in eight-chamber plastic Lab-Tek slides (Nunc) coated with rat tail collagen I (Becton Dickinson) at a density of 1 × 10^5 cells per well for primary murine hepatocytes, and of 2 × 10^5 cells per well for primary human hepatocytes cells, and cultured at 37°C, 5% CO₂, in DMEM medium as above supplemented with 10⁻⁷ M dexamethasone (Sigma) after complete cell adherence (12–24 hours).

**Evaluation of TNF-α cytotoxicity**

Toxicity of the cytokine to primary culture of hepatocytes or hepatoma cell lines in flat-bottom 96 wells (20 × 10^3 cells/well) was evaluated using a methylenedianilinediphenyl-tetrazolium bromide (MTT) assay. Briefly, cytokines were added in triplicate at decreasing concentrations. Medium was replaced 3 hours after sporozoite infection and every day thereafter up to day 4 (for rodent parasites) or 7 (for *P. falciparum*) with fresh medium containing the cytokine at the same concentration. Twenty-four hours after the last medium change, 110 μl of a solution containing 10 μl of MTT (Sigma) solution (5 mg/ml) and 100 μl of medium were added and the cultures incubated for a further 4 hours. The formazan crystals that were formed were dissolved using 100 μl of a 1:1 DMSO: ethanol solution. Optical density was read immediately at 570 nm with a reference wavelength at 630 nm [20].

**In vitro assay of sporozoite invasion of and development in hepatocytes and HepG2 cells**

After removal of medium from the culture chambers, ten thousands sporozoites were added in 100 μl of fresh supplemented medium with various quantities of TNF-α tested, and at different times during cultivation. Medium was replaced at −24, 0, 3, and 24 h after rodent malaria sporozoite inoculation, and at −24, 0, 3, 24 h and then every day up to day 5 after *P. falciparum* sporozoite inoculation of primary human hepatocytes with fresh medium containing or not the cytokine. In one experiment, supernatant was collected from wells containing human hepatocytes treated with TNF-α (100 ng/ml) or of for 2 days. *Plasmodium* sporozoites (10^5 in a 50 μl) were added to this supernatant (50 μl) or to fresh medium (50 μl). The final solution (100 μl) containing the sporozoite was added to the culture. Medium was replaced after 3 h, 24 h, and then every day up to day 5 after sporozoite inoculation. Experimental determination of the number of liver stage parasites was performed in triplicate or quadruplicate. Cultures were stopped 48 h (for rodent malaria species) or 5 days (for *P. falciparum*) after sporozoite infection, fixed with cold methanol and schizont numbers were assessed by immunofluorescence using antibodies recognizing *Plasmodium* liver stages as previously described [21,22] and were quantified by microscopic examination or using the Odyssey infra red imaging system (LI-COR Biosciences) [23]. Percentage of inhibition of the development is calculated by comparing the numbers of parasitic forms in the experimental wells versus control wells.

**Results**

**Effect of human TNF-α on HepG2-CD81 cells infected with murine Plasmodium species**

HepG2 is a hepatoma cell line easily propagated in vitro [24] that has been shown to sustain the development of the *P. berghei* [25]...
but not the *P. yoelii* [26] liver stages. Recently Silvie et al. [17] showed that HepG2 cells transduced with CD81 are thereby made permissive to *P. yoelii* development, providing a good system to study *P. yoelii* liver stage biology, thus reducing the need for the more tedious primary murine hepatocyte cultures. We employed this cell line to assess the role of TNF-α against the hepatic stages of malaria parasites.

When human TNF-α was added to HepG2-CD81 cultures over a four-day period centred on the time of sporozoite inoculation, Pyy265BY hepatic parasite development was inhibited in a dose dependent manner (Figure 1A). Significant inhibition was observed even at a low dose of 10 ng/ml. Only minor increases in the level of inhibition were obtained at doses above 100 ng/ml (Figure 1A). We then tested the influence of the timing of TNF-α...
addition on the level of inhibition observed. HepG2-CD81 cultures where the cytokine was added only 1 day before sporozoite inoculation were also significantly inhibited by 100 ng/ml of TNF-α (Figure 1B). However, no inhibition of parasite development could be observed when TNF-α was first added starting at the time of sporozoite inoculation or thereafter (Figure 1B). The inhibitory activity of TNF-α was specific to the parasites because TNF-α had no cytotoxic effect on infected or normal HepG2 cells as measured by the MTT assay, even when added at the highest doses used. Indeed, the optical density values obtained in wells containing untreated cells \([0.953 \pm 0.2 \text{ arbitrary units (A.U.)}]\) or cells treated for 4 days with 100 ng/ml TNF-α and infected with \(P. yoelii\) sporozoites \([1.29 \pm 0.05 \text{ A.U.}]\) did not differ significantly.

We next tested the effect of human TNF-α on \(PbA\) parasites, thus providing a reasonable comparison with the study of Schofield et al. where an inhibitory effect of human TNF-α against \(P. berghei\) NK65 strain was reported [10]. When human TNF-α at an inhibiting dose of 100 ng/ml was added to HepG2-CD81 cultures starting 48 h before sporozoite inoculation and over a four-day period until the end of the parasite cultivation period 48 h thereafter, \(PbA\) liver stage development was also inhibited in a dose dependent manner (Figure 2), though the magnitude of the inhibition was lesser than that observed for \(Pyy265BY\).

**Figure 2. Human TNF-α inhibits the pre-erythrocytic stage of \(PbA\).** HepG2/CD81 hepatoma cell cultures were treated with various concentrations of recombinant human TNF-α, 48 h prior to, at the time of, and then 3 h and 24 h after sporozoite inoculation. Cultures were stopped 48 h after sporozoite inoculation. Data are presented as the mean (± SD) reduction in \(PbA\) liver schizont numbers from triplicate experimental wells compared to those from 8 control wells. The number of liver schizonts in the control wells was \(357 \pm 31\). *\(p < 0.05\) versus control non-treated cultures (Kruskal-Wallis test, followed by Dunn test). The rate of infection \(PbA\) sporozoites for HepG2/CD81 hepatoma cell was between 0.3 to 2% depending on the experiment. Data are representative of two independent experiments with similar results. doi:10.1371/journal.pone.0017464.g002

**Effect of TNF-α on mouse hepatoma cell line Hepa 1–6 and primary mouse hepatocytes infected with murine \(Plasmodium\) species**

In order to test whether the findings obtained using HepG2-CD81 cells can be extended to other host cell/parasite combinations, we repeated the TNF-α treatment (100 ng/ml initiated at 48 h before sporozoite inoculation and maintained for the subsequent 48 h) with mouse hepatoma cells Hepa 1-6 and primary cultures of purified mouse hepatocytes, both of which sustain the growth of \(Plasmodium\) species that infect rodents [18,27]. Mouse TNFα significantly inhibited \(PbA\) in Hepa1-6 cells (Figure 3A) or in primary hepatocyte cultures (Figure 3B), whereas

**Figure 3. Effect of human or mouse TNF-α against the pre-erythrocytic stage of \(PbA\) and \(Pyy265BY\) grown in Hepa 1–6 hepatoma cells or primary hepatocytes cultures.** (A) Hepa 1–6 cells and (B) primary hepatocyte cultures were treated with 100 ng/ml of recombinant human or mouse TNF-α, 48 h prior to, at the time of, and then 3 h and 24 h after sporozoite inoculation. Cultures were stopped 48 h later. Data are presented as the mean (± SD) reduction in \(PbA\) liver schizont numbers at 48 h in triplicate experimental wells as compared to those enumerated in 6 control wells. In the control wells, there were \(110.3 \pm 13.1\) liver schizonts in Hepa1-6 and \(602 \pm 83.4\) in the primary mouse hepatocytes infected with \(PbA\), and \(25.5 \pm 3.6\) liver schizonts in Hepa1-6 and \(443.5 \pm 133.5\) in primary hepatocytes infected with \(Pyy265BY\). *\(p < 0.05\) versus control non-treated cultures (Kruskal-Wallis test, followed by Dunn test). The rate of infection for \(Pyy265\) sporozoites was 0.02-0.04% for Hepa1.6 cells and 0.1–2% for primary mouse hepatocytes. For \(PbA\) sporozoites, it was of 0.1–0.5% for Hepa1.6 cells and 0.5–1% for primary mouse hepatocytes. Data are representative of two independent experiments with similar results. ND, not done. doi:10.1371/journal.pone.0017464.g003
for Py265BY, inhibition was only observed in primary hepatocytes (Figure 3).

We next tested the effect of human TNF-α on mouse cells since it was shown previously that in vivo treatment with this cytokine inhibited P. berghei NK65 liver stage development [10]. However, human TNF-α may have an indirect inhibitory effect on the liver stage in situ, for e.g. by inducing the production of another anti-liver stage cytokine such as IL-6 by nonparenchymal liver cells. We wished to ascertain whether the inhibition noted above was due to direct interaction with hepatocytes [11]. The liver stage development of parasites (Py265BY or PbA) grown in primary mouse hepatocytes was not inhibited by treatment with human TNF-α (Figure 3B). These results indicate that parasite species are differentially susceptible to the inhibitory activity of TNF-α, and that this is influenced by the origin of the TNF-α as well as the type and origin of the host cells in which the parasites develop. It is worth noting that treatment with TNF-α had no cytotoxic effect on infected or non-infected primary mouse cells as measured by the MTT assay. The difference in the optical density values obtained for wells containing untreated cells (0.47±0.09 A.U.) or cells treated for 4 days with 100 ng/ml TNF-α and infected with P. yoelii sporozoites (0.41±0.05 A.U.) were not significant.

Effect of TNF-α on primary human hepatocytes infected with P. falciparum

We then tested the effect of TNF-α on the development of P. falciparum in human hepatocytes, a host/parasite combination of direct clinical relevance. We used highly purified human hepatocytes to prevent indirect effect of TNF-α on contaminating nonparenchymal cells as shown previously [11]. P. falciparum liver stage development was inhibited when the cultures were treated with human TNF-α at 100 ng/ml, but not 1 ng/ml, 24 h or 48 h prior to sporozoite inoculation and until day 5 thereafter (Figure 4). Inhibition was more pronounced when the hepatocytes were pre-incubated with human TNF-α 48 h as compared to 24 h before sporozoite inoculation. As for the other hepatocyte cells, treatment with TNF-α had no cytotoxic effect on primary human hepatocytes as measured by the MTT assay. The optical density values obtained for wells containing untreated cells (0.70±0.005 A.U.) or cells treated with for 4 days with 100 ng/ml TNF-α and infected with P. yoelii sporozoites (0.793±0.03 A.U.) did not differ significantly.

Absence of effect of nitric oxide derivatives and radical oxygen intermediates inhibitors on TNF-α mediated pre-erythrocytic stage inhibition

In order to determine how TNF-α inhibits liver stage parasite development, we used inhibitors that block the NO or the ROI pathways, both of which have been implicated previously in PE killing. First, we used S-methyl-thiourea (SMT), a competitive inhibitor of the inducible nitric oxide synthase [12]. Addition of SMT to cultures treated with 100 ng/ml of human TNF-α did not reverse the effect of the cytokine against Py265BY HepG2/CD81 (Figure 5A) or against P. falciparum in primary human hepatocytes (Figure 6A). We next tested whether inhibition was mediated via the ROI pathway by using N-acetyl-cysteine (NAC), the precursor of glutathione and a potent endogenous antioxidant [13]. Addition of NAC did not reverse TNF-α mediated inhibition of Py265BY in HepG2/CD81 (Figure 5B), or that of P. falciparum in primary human hepatocytes (Figure 6A). We also observed that SMT and NAC did not reverse the inhibitory effect of TNF-α on PbA-infected HepG2/CD81 hepatoma cells (data not shown).

A soluble mediator synthesized by human TNF-α-stimulated human hepatocytes prevents P. falciparum development

Since inhibition was observed only when cells were treated 48 h or 24 h before sporozoite infection but not on the time of sporozoite inoculation, we hypothesized that TNF-α-treated hepatocytes might release a parasite-inhibitory soluble mediator as previously shown for IL-1 or other inflammatory stimuli [28,29]. P. falciparum sporozoites in normal medium were added to supernatant medium obtained from human hepatocytes treated for 48 h with TNF-α (1/1 volume). The mixture was then added to fresh human hepatocytes to initiate the infection. A strong significant inhibition of sporozoite development was observed, and it reached levels similar to those induced by direct TNF-α pre-treatment of the cultures (Figure 6B). This showed that an inhibitory soluble mediator was produced by TNF-α-stimulated hepatocytes.

Discussion

The in vitro experiments presented here were designed to assess parameters, such as the origin of the cytokine, the origin of the
were treated 48 h (Figure 3) but not 24 h [11] before hepatocytes where an effect was observed only when the cultures These results differed from those obtained using primary mouse specific immune components against the malaria hepatic stages. It makes it a good surrogate in future studies of the role of non-

P. falciparum activity of TNF-α.

Figure 5. The effect of human TNF-α against Pyy265BY is not mediated by NO or ROI. HepG2/CD81 hepatoma cells treated or not with 100 ng/ml of human TNF-α together with or without SMT (A) or NAC (B) 48 h before, at the time of, and then 3 h and 24 h after sporozoite inoculation. Cultures were stopped 48 h later. Data are presented as the mean (± SD) reduction in liver schizont numbers in triplicate wells compared to the mean number in 6 control wells. The numbers of Pyy265BY liver schizonts in the 6 control wells were 145.5±9 (A), and 148±9 (B). The results are representative of three independent experiments. * p<0.05 versus control non-treated cultures (Kruskal-Wallis test, followed by Dunn test). doi:10.1371/journal.pone.0017464.g005

host cells, the parasite species, or the schedule of application that might affect the anti-liver stage activity of TNF-α. Different types of hepatocytes and hepatoma cell lines together with 3 Plasmodium species were used. Our main finding is that human TNF-α was able to inhibit the hepatic development of two rodent malaria species, P. yoelii and to a lesser extent P. berghei (Figure 1), and most importantly that of P. falciparum (Figure 4). We showed that this activity of TNF-α was dependent on the host cell type and on the schedule of this cytokine’s administration. Maximal inhibition could be obtained when human TNF-α was administered 48 h before sporozoite inoculation to HepG2/CD81 cells (Figure 1). Significant inhibition was still observed when cells were treated 24 h before sporozoite inoculation both in HepG2/CD81 infected with P. yoelii and in highly purified primary human hepatocytes infected with P. falciparum. The good concordance between the data derived from P. yoelii/HepG2-CD81 combination and that from the P. falciparum/human primary hepatocyte combination makes it a good surrogate in future studies of the role of non-specific immune components against the malaria hepatic stages. These results differed from those obtained using primary mouse hepatocytes where an effect was observed only when the cultures were treated 48 h (Figure 3) but not 24 h [11] before P. yoelii sporozoite inoculation. Of the different parameters that might account for this difference we favour those related to the TNF-α mechanism of action. Murine TNF-α and human TNF-α differ in their affinity to the various host TNF receptors. Human TNF-α signals only through TNFR1 in mouse cells [30] and, as shown here, it had no effect on primary mouse hepatocytes infected with P. yoelii or with P. berghei (Figure 3). Signalling by TNF-R1 signals is mediated through the TRAF pathway [31], however, in hepatocytes only TNFR1 mediates activation of NF-kB [32]. The NF-kB pathway is necessary for the induction of the NO or ROI in hepatocytes [33]. These two mediators have been shown to inhibit the Plasmodium liver stage [34,35]. We did not observe the induction of NO and ROI, which strongly suggests that it was TNFR2 but not TNFR1 that was involved in TNF-α signalling in infected hepatocytes. It has been proposed recently that malaria parasites manipulate their host hepatocytes to make them resistant to the apoptosis induced by TNF-α in vivo or in vitro [36] through interference with the NF-kB pathway [37] and consequently allowing them to escape the TNFR1-signalled cytotoxic effect of TNF-α. In addition, since signalling through TNF-R2 has also been involved in the necrotic effect of TNF-α.

Figure 6. A soluble mediator but not NO or RO intermediates synthesized by human TNF-α-stimulated human hepatocytes inhibits P. falciparum development. A. Primary human hepatocytes were treated or not with 100 ng/ml of human TNF-α together with or without SMT or NAC at 48 h before, at the time and every day for day 1 to day 5 after sporozoite inoculation. B. In the same experiment, supernatants from cells treated previously for 48 h with human TNF-α were added together with P. falciparum sporozoites to fresh human primary hepatocytes. Medium was changed after 3 hr and every day after sporozoite inoculation. In both experimental settings, cultures were stopped 5 days later. Data are presented as the mean (± SD) reduction in liver schizont numbers in triplicate wells to the mean number in 6 control wells and are derived from one of two experiments. The numbers of P. falciparum 5 day-liver schizonts in the 6 control wells were 179.2±26.1. * p<0.05 versus control non-treated cultures (Kruskal-Wallis test, followed by Dunn test). doi:10.1371/journal.pone.0017464.g006
hepatocytes and thus may be targeted by these two protease
Parasite proteases are necessary for sporozoite invasion in
able to prevent sporozoite infection and development [42].
protease inhibitors
reported previously that two other acute phase proteins, the
6 treatment of human hepatocytes. This suggest strongly that this
treatment blocks the induction of CRP stimulated by IL-1 or IL-
[38], we tested whether treatment with TNF-α induced infected
hepatocyte necrosis. Such an effect was ruled out because cell
cytotoxicity was not observed in the MTT assays conducted after
 treatment with TNF-α.

The fact that the inhibitory effect of TNF-α was observed only when cultures were pre-incubated with the cytokine suggested that
stimated hepatocytes secrete an inhibitory factor and/or that the
TNF-α treatment makes them refractory to infection. Host cell
refractoriness is unlikely because addition of the supernatant from
TNF-α-stimulated hepatocytes to the cultures was sufficient to
obtain hepatic parasite inhibition. TNF-α alone or together with
IL-6 and IL-1, is known to induce the synthesis of acute phase
response proteins by hepatocytes. Although the acute phase
response to inflammatory stimuli is evolutionary conserved,
species-specific differences exist [39,40]. IL-1 was previously
shown to prevent sporozoite development in human or rat
primary hepatocytes in vitro through the action of an acute phase
protein, the C-reactive protein (CRP) [11,29]. Human or rat C-
reactive proteins can bind sporozoite and prevent their invasion
and further development in hepatocytes [12,30]. However, Yap
et al. [41] have shown that CRP is not produced by human
hepatocytes after TNF-α stimulation. They also showed that TNF-
α treatment blocks the induction of CRP stimulated by IL-1 or IL-
6 treatment of human hepatocytes. This suggest strongly that this
acute phase protein does not mediate the TNF-α effect. It has been
reported previously that two other acute phase proteins, the
protease inhibitors α1-antitrypsin and α2-macroglobulin, were also
to prevent sporozoite infection and development [42].
Parasite proteases are necessary for sporozoite invasion in
hepatocytes [43] and thus may be targeted by these two protease
inhibitors. However, although TNF-α has been shown to increase
the synthesis of α1-antitrypsin [44] or α2-macroglobulin [45] in
HepG2 cells, it does not induce these molecules in human
hepatocytes [40]. Thus, the nature of the inhibitory mediator
secreted by human hepatocytes is still unknown and deserves
further study. In the mouse liver the profile of acute phase proteins
induced by inflammatory stimuli is different, for example mouse
hepatocytes do not synthesize CRP. Serum Amyloid A is induced by
TNF-α in mouse hepatocytes [46] and it might be responsible for
the inhibition that is consequent to TNF-α-stimulation of
mouse primary hepatocytes or mouse hepatoma cell lines.
However, Serum Amyloid A is not induced in human hepatocytes
by TNF-α stimulation [47] suggesting that other mediators might
be involved.

During malaria blood stage infection, the production of TNF-α
is increased [1,3], and these cytokine might modulate new liver
stage infections [48,49]. By extension, any systemic inflammations
or infections or more localized liver infections, of viral or bacterial
origin, that induces high level of TNF-α might also have an
inhibitory effect on the liver stages, which could consequently
influence the outcome of a subsequent blood infection and its
associated pathology [40,49].

Acknowledgments
LR, DM and GS are currently part of an official collaboration between
SiGn/A*STAR and INSERM (Laboratoire International Associé,
INSERM).

Author Contributions
Conceived and designed the experiments: ND JFF LR. Performed the
experiments: ND JFF ACG MM GS LR. Analyzed the data: ND JFF DM
GS LR. Contributed reagents/materials/analysis tools: JMC AJFL GJvG
RWS JMS LH. Wrote the paper: ND GS LR.

References
necrosis factor and disease severity in children with falciparum malaria. N
tumor necrosis factor-alpha and interleukin-6 serum levels as markers for
TNF concentration in fatal cerebral, non fatal cerebral, and uncomplicated
In vitro stimulation of human primary hepatocytes by IL-1 and IL-6.
synthesis of 1-antitrypsin [44] or α2-macroglobulin [45] in

13. Cotgreave IA (1997) N-acetylcysteine: pharmacological considerations and
(2004) A Plasmodium berghei reference line that constitutively expresses GFP at
a high level throughout the complete life cycle. Mol Biochem Parasitol 137: 23–33.
16. Ponnusurali T, Lensen AHW, Mensiens JHET (1985) An automated large-
scale culture system of Plasmodium falciparum using tangential flow filtration
(2006) Expression of human CD81 differently affects host cell susceptibility to
malaria sporozoites depending on the Plasmodium species. Cell Microbiol 8:
1134–1146.
multiple antigen peptides containing defined T and B epitopes of the
Plasmodium yoelii circumsporozoite protein: antibody-mediated protection and
Apical Membrane Antigen 1 during Invasion of Hepatocytes by Plasmodium
shock like protein epitope expressed on the infected hepatocyte surface is the
target of antibody-dependent cell-mediated cytotoxic mechanisms by
heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitol Res
80: 16–21.
method for high-throughput screening of drug activity on Plasmodium liver
lines secrete the major plasma proteins and hepatitis B surface antigen. Science
268: 497–499.
exorhynhotrophic stage of Plasmodium berghei in a hepatoma cell line. Am J Trop
41. Yap SH, Moshage HJ, Hazenberg BPC, Roelofs HMJ, Bijzet J, et al. (1991) Tumor necrosis factor (TNF) inhibits interleukin IL-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1091: 405–408.